Astellas Pharma

Astellas sarà presente al 99° Congresso Nazionale della Società Italiana di Urologia, che si terrà a Riccione dal 28 al 31 ottobre. Un importante appuntamento di confronto e aggiornamento per la comunità urologica, che metterà al centro l’innovazione, la ricerca e le nuove prospettive della pratica clinica, con l’obiettivo di migliorare la qualità delle cure e la vita dei pazienti. In un contesto scientifico in continua evoluzione, come cambia la gestione del carcinoma prostatico ormono-sensibile? Noi di Astellas ne parleremo in un simposio dedicato alle più recenti evidenze scientifiche nel setting HSPC, con particolare attenzione alla corretta identificazione dei pazienti e alla tempestività delle scelte terapeutiche, elementi fondamentali per ottimizzare gli esiti clinici. Se sei un professionista sanitario e parteciperai al Congresso SIU, ti aspettiamo venerdì 30 ottobre alle 13 nella Sala Bracci del Palazzo dei Congressi di Riccione. Per tutta la durata del Congresso ci trovi agli stand #12-13-37.

Shaping the Future of Transplantation Congratulations to Dr. Frederik Haupenthal, Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna. He is the winner of the Young Investigator Award 2026 – Clinical and was honoured at the Austrotransplant Congress for his presentation: "Torque Teno Virus-Guided vs. Standard Immunosuppression in Kidney Transplant Recipients: The TTVguideIT Randomised Controlled Trial." Scientific progress in transplantation depends on the curiosity, dedication and innovation of the next generation of researchers and clinicians. Through its longterm support of the Young Investigator Award, Astellas is proud to contribute to the advancement of clinical and translational transplantation research and to encourage young talents shaping the future of transplantation. Congratulations on this well-deserved recognition, and thank you to the Austrotransplant community for its continued commitment to scientific excellence and collaboration. The Young Investigator Award is supported by Astellas. #Transplantation #ClinicalResearch #YoungInvestigatorAward #MedicalEducation MAT-AT-NON-2026-00044 | Date of preparation 08/2026

Die Zukunft der Transplantation gestalten Herzliche Gratulation an Dr. Frederik Haupenthal, Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Gewinner des Young Investigator Award - Klinisch 2026 mit dem Beitrag «Torque Teno Virus-Guided vs. Standard Immunosuppression in Kidney Transplant Recipients: The TTVguideIT Randomised Controlled Trial», der im Rahmen des Austrotransplant-Kongresses verliehen wurde. Wissenschaftlicher Fortschritt in der Transplantationsmedizin lebt vom Engagement, der Neugier und den Ideen der nächsten Generation von Forschenden, Ärztinnen und Ärzten. Mit der langfristigen Unterstützung des Young Investigator Award engagiert sich Astellas für die Förderung der klinischen und translationalen Transplantationsforschung sowie junger Talente, die die Zukunft der Transplantationsmedizin aktiv mitgestalten. Wir gratulieren herzlich zu dieser verdienten Auszeichnung und danken der Austrotransplant-Community für ihren kontinuierlichen Einsatz für wissenschaftlichen Austausch und Exzellenz. Der Young Investigator Award wird von Astellas unterstützt. #Transplantation #ClinicalResearch #YoungInvestigatorAward #MedicalEducation MAT-AT-NON-2026-00043 | Date of preparation 08/2026

Scientific innovation matters most when it connects with the realities of cancer care and the needs of the people it is intended to serve. Ahead of #ESMO2026, Astellas leaders Moitreyee Chatterjee-Kishore, Ph.D., MBA and Emad Siddiqui discuss how combining deep disease biology, innovative treatment approaches, real-world evidence and clinical experience can help turn scientific progress into new possibilities for people with difficult-to-treat cancers. Read the full conversation: https://lnkd.in/gXHHGxFm #AstellasPioneeringScience #oncology #CancerResearch

A decade ago, CLDN18.2 was a scientific hypothesis. Today, it is helping reshape the treatment landscape for patients with some of the hardest-to-treat cancers. Ahead of #ESMO26, we reflect on the evolution of this important biomarker with Fierce Biotech, sharing insights from ten years of progress and the questions that will shape where we go next. Learn more about our long-standing commitment to CLDN18.2-directed innovation: https://lnkd.in/enDzraNH #AstellasPioneeringScience #oncology #CancerResearch

For healthcare professionals only. Attending #ESMO26? Join us this Sunday, 25 October from 13:00-14:30 for our Satellite Symposium in the Leon Auditorium, Hall 4, IFEMA, where leading experts will come together to discuss the importance of early treatment decisions in advanced prostate and urothelial cancer. Learn more: https://lnkd.in/e3dzs6rT Save the date and join the conversation. #ProstateCancer #BladderCancer #UrothelialCancer #oncology #ESMO26